Purchase this article with an account.
S. Oliver, T. A. Young, M. Chun, J. Moral, B. R. Straatsma; Prospective Surveillance of Visual Function in Patients With Ocular Melanoma Undergoing Iodine-125 Plaque Brachytherapy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5262.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the protocol for visual function assessment and the baseline enrollment characteristics in a prospective cohort study of patients with choroidal melanoma undergoing Iodine-125 plaque radiotherapy.
In a prospective study of patients with choroidal melanoma enrolled between March 2005 and November 2006, ophthalmic evaluation was performed prior to Iodine-125 plaque brachytherapy and baseline findings are reported.
The protocol for baseline assessment includes ophthalmic history, standardized visual acuity, contrast sensitivity, and color vision assessment, comprehensive ophthalmic examination, fundus photography, fluorescein angiography, and ultrasonography. Thirty patients (mean age 61 ± 12) were enrolled with a mean tumor height of 4.01 mm. Tumor location was macular in 7 patients, posterior to the equator in 15, equatorial in 5, and anterior to the equator in 3. Mean ETDRS acuity was 47 letters, mean Pelli-Robson contrast sensitivity score was 29, and mean HRR score was 12. Visual function was reassessed at 12 month intervals.
Radiation maculopathy, papillopathy, and proliferative retinopathy are known complications of Iodine-125 plaque brachytherapy for choroidal melanoma. Prospective assessment of visual function will allow better understanding of the ocular effects of radiation therapy.
This PDF is available to Subscribers Only